Precise Treatment System of Biliary Malignancies Based on Special Disease Database

NCT ID: NCT03499782

Last Updated: 2018-04-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-05-25

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Malignant tumors of biliary system lack standard treatment and precise prognosis assessment methods. This study including 12 hospitals, collecting clinical and follow-up data of patients with biliary malignant tumors including cholangiocarcinoma and gallbladder carcinoma in recent 10 years, aim to build a special disease database, then use Bayesian networks and importance theory to establish a mathematical model to assess treatment strategies and prognosis accurately. At the same time, data on biliary malignant tumors newly treated by multicenters from 2018 to 2020 will be included to validate, adjust and refine the models to guide clinical individualized precise treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cholangiocarcinoma Gall Bladder Carcinoma Biliary System Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of biliary malignancy including gallbladder carcinoma or cholangiocarcinoma verified by pathological results
* Must be able to undergo surgery
* Undergoing radical surgery for biliary malignancy (R0 or R1 resection)
* Not complicated with other malignancy
* No other treatments before and during surgery, such as radiotherapy and chemotherapy.

Exclusion Criteria

* Non-primary gallbladder or cholangiocarcinoma
* With distant metastasis (M1 phase)
* Incomplete follow-up data
* Died within 30 days after surgery.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

First Affiliated Hospital Xi'an Jiaotong University

OTHER

Sponsor Role collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

Sponsor Role collaborator

The First Affiliated Hospital of Dalian Medical University

OTHER

Sponsor Role collaborator

Shanghai Zhongshan Hospital

OTHER

Sponsor Role collaborator

Southwest Hospital, China

OTHER

Sponsor Role collaborator

Tianjin Medical University Cancer Institute and Hospital

OTHER

Sponsor Role collaborator

Sun Yat-sen University

OTHER

Sponsor Role collaborator

Affiliated Hospital of North Sichuan Medical College

OTHER

Sponsor Role collaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

Sponsor Role collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

Sponsor Role collaborator

Eastern Hepatobiliary Surgery Hospital

OTHER

Sponsor Role collaborator

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zhaohui Tang

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zhimin Geng, MD,PhD

Role: STUDY_DIRECTOR

the first affiliated hospital of xi'an Jiaotong univerisity

Peng Gong, MD,PhD

Role: STUDY_DIRECTOR

the first affiliated hospital of Dalian medical univerisity

Yu He, MD,PhD

Role: STUDY_DIRECTOR

Southwest Hospital, China

Shengping Li, MD,PhD

Role: STUDY_DIRECTOR

Cancer Institute and Hospital Affiliated to Sun Yat-sen University

Yinghe Qiu, MD,PhD

Role: STUDY_DIRECTOR

Eastern Hepatobiliary Surgery Hospital

Zhi Dai, MD,PhD

Role: STUDY_DIRECTOR

Shanghai Zhongshan Hospital

Tianqiang Song, MD,PhD

Role: STUDY_DIRECTOR

Tianjin Medical University Cancer Institute and Hospital

Yudong Qiu, MD,PhD

Role: STUDY_DIRECTOR

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Jianying Lou, MD,PhD

Role: STUDY_DIRECTOR

Second Affiliated Hospital, School of Medicine, Zhejiang University

Jingdong Li, MD,PdD

Role: STUDY_DIRECTOR

Affliated Hospital of North Sichuan Medical College

Wenlong Zhai, MD,PhD

Role: STUDY_DIRECTOR

The First Affiliated Hospital of Zhengzhou University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zhaohui Tang

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zhaohui Tang, MD,PhD

Role: CONTACT

+86 13601789458

Miaoyan Wei, MD,PhD

Role: CONTACT

+86 18516574578

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Miaoyan Wei

Role: primary

+86 18516574578

Zhaohiu Tang Tang

Role: backup

+8613601789458

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

XHEC-JDYXY-2018-002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Questionnaire Survey for Biliary Tract Cancers
NCT04731220 ENROLLING_BY_INVITATION